Skip to content

MDMA research published in 2023

Page 2 of 7: studies 21 to 40 of 125, newest first. Back to the MDMA overview

Studies

Theory of Technomagic: Spells, Ecstasy and Possessions in Digital Culture

Comunicação e Sociedade October 17, 2023 Vincenzo Valentino Susca 1 citation

The rituals, ceremonies and effervescence of the sacred manifest themselves in digital culture not only through the proliferation of new religious cults. They do so through the online actualisation of traditional religious forms but also the spiritual elevation of objects (Houtman & Meyer, 2012), practices (Carolyn, 2014) or ephemeral, playful and dreamlike images (Susca, 2016). In most cases,...

Repurposing of recreational drugs: will these new ‘medicines’ (e.g., psychedelics, psilocybin, cannabinoids, LSD, MDMA, ketamine) deliver short- or longer-term benefits for those with depressive or other mood disorders?

Research Directions Depression October 13, 2023 Ian B. Hickie, F. Markus Leweke, Allan H. Young 1 citation

In recent years, there has been considerable enthusiasm among research groups focused on developing novel therapies for treatment-resistant depression, and a wider community that has had experiences using recreational drugs, in more systematic evaluation of the therapeutic value of these compounds (Goodwin et al., 2022; Young, 2023). This has also been associated with advocacy for...

Bedside to bench: the outlook for psychedelic research

Frontiers in Pharmacology October 2, 2023 Victor P Acero, Emily S Cribas, Kevin D Browne et al. 20 citations

There has recently been a resurgence of interest in psychedelic compounds based on studies demonstrating their potential therapeutic applications in treating post-traumatic stress disorder, substance abuse disorders, and treatment-resistant depression. Despite promising efficacy observed in some clinical trials, the full range of biological effects and mechanism(s) of action of these compounds...

OR17-01 Novel Provocation Test With MDMA (‘Ecstasy’) Reveals Oxytocin Deficiency As A New Pituitary Entity In Patients With Central Diabetes Insipidus - A Randomized Placebo-Controlled Trial

Journal of the Endocrine Society October 1, 2023 Cihan Atila, Friederike Holze, Rakithan Murugesu et al.

Abstract Disclosure: C. Atila: None. F. Holze: None. R. Murugesu: None. N. Rommers: None. N. Hutter: None. N. Varghese: None. C.O. Sailer: None. A. Eckert: None. M. Heinrichs: None. M. Liechti: None. M. Christ-crain: None. Introduction: Despite adequate treatment, patients with arginine vasopressin deficiency (AVP-D), known as central diabetes insipidus (cDI), often report psychological...

DOI: 10.1210/jendso/bvad114.1307 (opens in new tab) Anxiety Provocation test Oxytocin Placebo +5

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Nature Medicine October 1, 2023 Jennifer Mitchell, Marcela Ot’alora G., Bessel Van der Kolk et al. 400 citations

This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical therapy in participants with moderate to severe post-traumatic stress disorder (PTSD). Changes in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total severity score (primary endpoint) and...

Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.

Current Psychiatry Reports October 1, 2023 Aaron Wolfgang, Charles W Hoge 15 citations

This review discusses the current and projected landscape of psychedelic-assisted therapy (PAT), with a focus on clinical, legal, and implementation considerations in Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare systems. 3,4-Methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted therapy have shown promising outcomes in efficacy, safety, tolerability, and...

New research finds MDMA effective in treating severe PTSD

Mental Health Weekly September 25, 2023 Valerie A. Canady

The third part of a new study assessing MDMA‐assisted therapy, a psychedelic drug also known as Ecstasy, has revealed improvement in diverse individuals suffering with severe post‐traumatic stress disorder (PTSD). The study, “MDMA‐assisted therapy for moderate to severe PTSD: a randomized, placebo‐controlled phase 3 trial,” published Sept. 14 in Nature Medicine.

Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report.

Journal of Medical Case Reports September 23, 2023 Tianyi Hui, Song Guo 2 citations

Current evidence linking the development of Parkinson's disease after the use of 3,4-methylenedioxymethamphetamine is mixed and limited, with only a few positive case reports demonstrating this. We examine this interesting case of a 49-year-old Chinese gentleman who used 3,4-methylenedioxymethamphetamine and subsequently developed early onset Parkinson's disease at age 38 years. He had a family...

DOI: 10.1186/s13256-023-04147-x (opens in new tab) Full text (opens in new tab) 3,4-Methylenedioxymethamphetamine MDMA Case report Parkinson’s disease

MDMA-Assisted Therapy for PTSD Shows Promise for Patients of Diverse Backgrounds

Psychiatric News September 22, 2023

Back to table of contents Previous article Next article Clinical & ResearchFull AccessMDMA-Assisted Therapy for PTSD Shows Promise for Patients of Diverse BackgroundsSearch for more papers by this authorPublished Online:22 Sep 2023https://doi.org/10.1176/appi.pn.2023.10.10.60AbstractMDMA appears to enhance the ability of individuals with PTSD to benefit from psychotherapy by softening their...

Drug-induced social connection: both MDMA and methamphetamine increase feelings of connectedness during controlled dyadic conversations

Scientific Reports September 22, 2023 Hanna Molla, Royce Lee, Sonja Lyubomirsky et al. 28 citations

MDMA is a stimulant-like drug with distinctive empathogenic effects. Its pro-social effects, such as feelings of connectedness, may contribute to both its popularity as a recreational drug and its apparent value as an adjunct to psychotherapy. However, little is known about the behavioral processes by which MDMA affects social interactions. This investigation examined the effects of MDMA (100...

From the party to the therapy – MDMA as an alternative for the existing methods of Post-traumatic Stress Disorder treatment

Current Problems of Psychiatry September 22, 2023 Wiktoria Bojarska, Karolina Bury, Radosław Januszczak et al.

Introduction: Post-traumatic Stress Disorder (PTSD) is a mental illness caused by exposure to a traumatic event. The current treatment includes trauma-focused psychotherapy along with selective serotonin reuptake inhibitors (SSRI). It is estimated that for about 40-60% of patients it does not bring the desired improvement, which prompted scientists to look for new methods of pharmacotherapy....

MDMA targets miR-124/MEKK3 via MALAT1 to promote Parkinson’s disease progression

Molecular Biology Reports September 9, 2023 Xin Geng, Shipeng Li, Jinghui Li et al. 3 citations

BACKGROUND: Parkinson's disease (PD) is a well-known neurodegenerative disease that is usually caused by the progressive loss of dopamine neurons and the formation of Lewy vesicles. 3,4-Methylenedioxymethamphetamine (MDMA) has been reported to cause damage to human substantia nigra neurons and an increased risk of PD, but the exact molecular mechanisms need further investigation. METHODS: MPTP-...

The Effects of Folic Acid on Testicular Histology, Sperm Quality, and Spermatogenesis Indices Following 3,4-Methylenedioxymethamphetamine Exposure in Adult Male Rats

Addiction and Health September 4, 2023 Iman Rad, Arezoo Saberi, Najmeh Sadat Koochakzadeh-Nematollahi et al. 6 citations

Background: There is an increasing concern over acute exposure of amphetamine and its derivative such as3,4-methylenedioxymethamphetamine (MDMA) on male reproductive toxicity. Supplementary vitamins canreduce the oxidative stresses and repair the damages on reproductive organs. This experimental study wasconducted to evaluate the effects of folic acid (FA) on reproductive indices, the...

DOI: 10.22122/ahj.v13i1.295 (opens in new tab) Full text (opens in new tab) Folic acid N-methyl-3,4-methylenedioxyamphetamine Spermatozoa Spermatogenesis +1

Striatal Iron Deposition in Recreational MDMA (Ecstasy) Users.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging September 2023 Rebecca C Coray, Jatta Berberat, Josua Zimmermann et al.

The common club drug MDMA (also known as ecstasy) enhances mood, sensory perception, energy, sociability, and euphoria. While MDMA has been shown to produce neurotoxicity in animal models, research on its potential neurotoxic effects in humans is inconclusive and has focused primarily on the serotonin system. We investigated 34 regular, largely pure MDMA users for signs of premature...

Revisión sobre estudios del uso de microdosificación con alucinógenos que combinan técnicas psicoterapéuticas con administraciones de LSD, MDMA o Psilocibina, como complementos farmacológicos en psicopatologías crónicas, trastornos moderados, altos, graves o crónicos, así como en enfermedades potencialmente mortales

September 1, 2023 Aldo Chiquini

La microdosificación (o las microdosis) hace referencia al ingerir una dosis muy baja de una sustancia psicodélica, donde no hay efectos de alteraciones cognitivas, afectivas, perceptivas y neurofisiológicas. Recientemente instituciones como la MAPS, la Universidad Johns Hopkins, el Imperial College of London y la FDA, a dicha microdosificación le han designado como «terapia innovadora», ya que...

Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder.

Psychedelic Medicine September 1, 2023 Harpreet Kaur, Sedat Karabulut, James W Gauld et al. 10 citations

Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental syndromes diagnostically characterized by deficits in social communication and social interaction and repetitive, inflexible patterns of behaviors, interests, and thoughts. ASD affects people worldwide, irrespective of race, ethnicity, or socio-economic status, with debilitating effects on employment and interpersonal...

Adverse drug effects as a deterrent against willingness to use in the future among nightclub/festival attendees.

Drug and Alcohol Review September 1, 2023 Joseph J Palamar 5 citations

It is largely unknown whether adverse effects experienced from recreational drug use affect willingness to use again. This study determined whether adverse effects from select party drugs affect reported willingness to use again in the next month among a high-risk population-people who attend electronic dance music parties at nightclubs or dance festivals. Adults (age ≥ 18) entering...

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Scientific Reports August 22, 2023 Hannes Kettner, Stephen Ross, Richard J. Zeifman et al. 31 citations

Abstract Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health care providers and patients. Co-use of 3,4-Methylenedioxy methamphetamine (MDMA) with psilocybin/LSD anecdotally reduces challenging...

Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City

Journal of Psychoactive Drugs August 21, 2023 Caroline Rutherford, Austin Le, Joseph J Palamar et al. 2 citations

Few epidemiological studies have focused on seasonal variation in the use of common psychedelics and party drugs among nightclub and festival attendees, typically those who attend electronic dance music (EDM) events. We sought to determine whether the use of different drug types varies seasonally within this population. Across 15 seasons from summer 2017 through fall 2022, we surveyed 3,935...